A significant reduction of frequency and absolute number of peripheral CD4+ and CD8+CD20+ cells in peripheral blood was confirmed by von Essen et al. in PP-MS patients treated with DMF for 48 weeks [32]. This evidence concerns the gene MS4A1 and myeloid sarcoma.